Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Statins-a panacea?].

G Klose1

  • 1Innere Klinik, Zentralkrankenhaus links der Weser, Senator-Wessling-Strasse 1, 28277 Bremen, Germany.

Zeitschrift Fur Kardiologie
|March 17, 2004
PubMed
Summary

Statins effectively reduce cardiovascular event risk by an average of 23% in patients with coronary heart disease. Research confirms their safety and efficacy across diverse patient groups, including the elderly and those with normal lipid levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Primary disorders of lipid metabolism: their place in current dyslipidemia guidelines and treatment innovations].

Innere Medizin (Heidelberg, Germany)·2023
Same author

MMW Fortschritte der Medizin·2020
Same author

MMW Fortschritte der Medizin·2019
Same author

[Efficacy and safety of statin therapy in old age].

Der Internist·2019
Same author

MMW Fortschritte der Medizin·2019
Same author

MMW Fortschritte der Medizin·2019

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Context:

  • Statins are widely prescribed for coronary heart disease.
  • Previous studies like ALLHAT yielded mixed results on mortality reduction.
  • ASCOT and PROSPER trials highlighted efficacy in specific populations.

Purpose:

  • To evaluate the overall therapeutic value and safety of statin therapy.
  • To reconcile conflicting findings from major clinical trials.
  • To confirm statin efficacy in broader patient demographics.

Summary:

  • Statins demonstrate an average 23% relative risk reduction for cardiovascular events.
  • Despite ALLHAT's limitations, ASCOT and PROSPER confirm statin benefits in normolipemic hypertensives and the elderly.
  • Safety data, exemplified by the Prospective Pravastatin Pooling Project, shows comparable adverse event rates to placebo.

Impact:

  • Statins remain a cornerstone therapy for cardiovascular disease prevention.
  • Evidence supports statin use beyond hyperlipidemia, including in normolipemic individuals.
  • The favorable safety profile reinforces statins as a reliable treatment option.

Related Experiment Videos